Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment
Status:
Suspended
Trial end date:
2022-04-23
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies side effects and best dose of pevonedistat when given together
with ixazomib in treating patients with multiple myeloma that has come back or does not
respond to treatment. Pevonedistat and ixazomib may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.